Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period
| Autor: | Sergi Mas, Antonio Lobo, Patricia Gassó, Jerónimo Saiz-Ruiz, Manuel J. Cuesta, Anna Mané, Joan Albert Arnaiz, Miguel Bernardo, Josefina Castro-Fornieles, Mara Parellada, Amalia Lafuente, Clemente García, Daniel Boloc, Natalia Rodríguez, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Ana González-Pinto, Miquel Bioque |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Psychosis Candidate gene Time Factors Adolescent Genotype Side effect medicine.medical_treatment Period (gene) Weight Gain Polymorphism Single Nucleotide Young Adult 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Metabolic Diseases Internal medicine medicine Humans Genetic Predisposition to Disease Pharmacology (medical) Obesity Antipsychotic Pharmacology First episode business.industry medicine.disease 030227 psychiatry Psychiatry and Mental health Phenotype Psychotic Disorders Female business 030217 neurology & neurosurgery Antipsychotic Agents Follow-Up Studies |
| Zdroj: | Journal of Psychopharmacology. 34:514-523 |
| ISSN: | 1461-7285 0269-8811 |
| DOI: | 10.1177/0269881120903462 |
| Popis: | Aims: Patients with a first episode of psychosis (FEP) often display different metabolic disturbances even independently of drug therapy. However, antipsychotic (AP) treatment, especially with second-generation APs, is strongly linked to weight gain, which increases patients’ risk of developing obesity and other metabolic diseases. There is an important genetic risk component that can contribute to the appearance of these disturbances. The aim of the present study was to evaluate the effect of polymorphisms in selected candidate genes on obesity and other anthropometric and metabolic traits in 320 AP-treated FEP patients over the course of a 2-year follow-up. Methods: These patients were recruited in the multicentre PEPs study (Phenotype−genotype and environmental interaction; Application of a predictive model in first psychotic episodes). A total of 127 validated single nucleotide polymorphisms (SNPs) in 18 candidate genes were included in the genetic analysis. Results: After Bonferroni correction, SNPs in ADRA2A, FTO, CNR1, DRD2, DRD3, LEPR and BDNF were associated with obesity, abdominal circumference, triglycerides, HDL cholesterol, and/or percentage of glycated haemoglobin. Conclusions: Although our results should be interpreted as exploratory, they support previous evidence of the impact of these candidate genes on obesity and metabolic status. Further research is required to gain a better knowledge of the genetic variants that can be considered relevant metabolic risk factors. The ability to identify FEP patients at higher risk for these metabolic disturbances would enable clinicians to better select and control their AP treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|